Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0TQMPJ
ADC Name
3G10-TG6-vcMMAD
Synonyms
3G10 TG6 vcMMAD
   Click to Show/Hide
Organization
Pfizer Inc.
Drug Status
Investigative
Indication
In total 4 Indication(s)
Adult T acute lymphoblastic leukemia [ICD11:2A90]
Investigative
Burkitt lymphoma [ICD11:2A85]
Investigative
Mature T-cell lymphoma [ICD11:2A90] [ICD11:2A90]
Investigative
Plasma cell myeloma [ICD11: 2A83]
Investigative
Drug-to-Antibody Ratio
1.9
Antibody Name
3G10-TG6
  Antibody Info 
Antigen Name
C-X-C chemokine receptor type 4 (CXCR4)
  Antigen Info 
Payload Name
Monomethyl auristatin D
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Mc-Val-Cit-PABC
  Linker Info 
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
1.9
nM
CVCL_0597
Burkitt lymphoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 1.90 nM Positive CXCR4 expression (CXCR4+++/++)
Method Description
Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model Burkitt lymphoma Ramos cells CVCL_0597
References
Ref 1 Anti-cxcr4 antibodies and antibody-drug conjugates.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.